Good morning. My name is David Woodhouse, and I'm the Chief Executive Officer of NGM Biopharmaceuticals. I'm pleased to welcome you to the NGM Biopharmaceuticals 2021 Annual Meeting of Stockholders. The meeting will now officially come to order. The time is now 7:30 A.M. Pacific Time on Tuesday, June 8th, 2021, and the polls are now open for voting on all matters to be presented. As you know, we are hosting today's meeting through a virtual online platform hosted by Q4. This meeting is being recorded and will be archived for one year after the date of the annual meeting at www.virtualshareholdermeeting.com/ngm2021. Before we proceed with the formal business of the meeting, I'd like to introduce to you the members of the board and the business team who are with us today. The other members of the board with us virtually today are William J. Rieflin, our executive chairman, Jin-Long Chen, our founder and chief scientific officer, David V. Goeddel, our lead independent director, Shelly D. Guyer, Carole Ho, Suzanne Hooper, Mark Leschly, and Mac Tichenor. I would like to particularly extend NGM's gratitude to David Schnell and Mac Tichenor, who are moving off the board at the conclusion of this meeting for their many years of service to NGM. Thank you, David and Mac. The other members of NGM team with us virtually today are Valerie Pierce, our senior vice president and general counsel, and she will act as the meeting secretary and also serve as inspector of election. Also with us is Siobhan Nolan Mangini, our chief financial officer. I would also like to introduce Guy Richardson of Ernst & Young, the company's independent registered public accounting firm, who is also in attendance virtually and able to respond to appropriate questions. Andrew Caballo from Q4 is also present. We will proceed with the formal business of the meeting in the order set forth in the notice of annual meeting and proxy statement provided to stockholders. First, we will present the two proposals submitted for approval in the proxy. We will then take questions related to the proposal after they have been presented and announce the preliminary results of the voting. Stockholders who are attending this meeting with a valid control number may submit questions or comments on the proposals or for the Q&A portion of this meeting by clicking the Q&A button in the bottom right corner of the virtual meeting screen. We will try to answer questions submitted that are germane to the proposals and/or this meeting, time permitting. As I mentioned earlier, the polls are open for voting on all matters presented. After I describe the items to be voted on, we will close the polls. We will not accept ballots, proxies, revocations, or other changes after the polls close. If you have already submitted your vote by proxy and do not wish to change your vote, you do not need to do anything at this meeting, and your shares will be voted as previously instructed. If you intend to vote or wish to change your vote, you must submit your final vote online now in order for it to be counted. If you have not voted, I encourage you to vote online now. After the formal part of our meeting has concluded, we will answer any appropriate questions you may have. The rules of conduct for this meeting are available on our website at www.ngmbio.com under the Investors tab or by clicking on the link Materials on your virtual meeting screen, which will bring you to the appropriate section of our website. In order to conduct an orderly meeting, we ask that you follow these rules. Please submit your questions now to make sure they are received in a timely fashion for our review and response. Will the secretary please report at this time with respect to the mailing of the notice of the meeting and the stockholders list? I have at this meeting a complete list of the holders of record of the company's common stock on April 16th, 2021, which was the record date for this meeting. A list of stockholders of record is available for inspection by stockholders of record during this meeting for any reason germane to this meeting. Please click on the link "Proxy Materials" on your virtual meeting screen, which will bring you to the appropriate section of our website to coordinate the viewing of this list. I also have an affidavit certifying that commencing on April 29, 2021, a notice of annual meeting of stockholders of the company was deposited in the U.S. mail to all stockholders of record as of the record date. At this time, I'm appointing Ms. Pierce to act as inspector of election at this meeting. Ms. Pierce has taken and subscribed to a customary oath of office to execute her duties with strict impartiality. We will file this oath with the records of the meeting. Her function is to decide upon the qualifications of voters, accept their votes, and, when balloting on all matters is completed, to tally the final votes. Will the secretary please report at this time with respect to the existence of a quorum? I have confirmed in my role as inspector of elections that proxies have been received for 69,221,451 of the 76,956,135 shares of common stock outstanding on the record date. This represents approximately 90% of the total number of outstanding shares on the record date. This constitutes a quorum for today's meeting, and we may now carry out the official business of the meeting. We will now proceed with the formal business of this meeting. After all the proposals have been described, we'll answer any questions related to the proposals that have been submitted online. There are two proposals to be considered by the stockholders at this meeting. The first item of business is the election of two Class II directors to serve until the 2024 annual meeting and until their successors are elected. The nominees for Class II directors are Roger M. Perlmutter and Jin-Long Chen. The second and final item of business today is the ratification of the selection by the audit committee of the board of directors of Ernst & Young LLP as the independent registered public accounting firm of the company for the fiscal year ending December 31st, 2021. We will now review if there are any questions submitted about the proposals before we close the polls. As a reminder, we will only review and answer questions at this time that pertain to the proposals. Valerie, are there any questions? David, there are no questions at this time. The time is now 7:37 A.M. Pacific Time, and the polls are now closed for voting. Do we have the results of the voting? The report of the inspector of election covering the proposals presented at this meeting is as follows. First, the proposal to elect Roger Perlmutter and Jin-Long Chen as Class II directors of the company is carried. Second, the selection of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2021, is ratified. We expect to report our preliminary voting results, or, if available to us on a timely basis, our final voting results on a current report on Form 8-K to be filed with the SEC within four business days after the end of this meeting. If not earlier reported, we expect to report our final voting results in an amendment to the Form 8-K within four business days after the final results are known to us. This concludes the formal portion of today's meeting, and the annual meeting is now concluded. We will now entertain any other appropriate questions from stockholders. David, we have a non-proposal -related question that was submitted by a stockholder, and this is, "Why are we continuing to fund aldafermin in F4 patients when," and I will quote the question, "when the press release issued May 24th, 2021, implied to the industry that aldafermin is dead?" Okay. Thank you for the question. The aldafermin we are not taking forward in F2, F3 NASH patients. Aldafermin in F4 patients is a separate trial called ALPINE 4 that is being conducted for a year in length. We think it's of benefit to understanding the mechanism of aldafermin on a trial that's already well underway to explore the effect of the drug for a twice as long treatment period. ALPINE 2/3 was a six-month treatment period. ALPINE 4 is a year. It's actually quite a different patient population, and given the results we've seen to date, we think it's worth completing that trial to understand the opportunity that may exist in these more advanced F4 patients that are frankly underserved for any current treatment, and particularly with a drug with a profile such as aldafermin, could have an attractive market opportunity eventually if that trial were to succeed. Any other questions? David, I see no further questions in the queue. I just wanted to note that in our discussion today, there may have been forward-looking statements, and our actual results may differ materially from those discussed here. Additional information about factors that could cause such a difference can be found in our most recently filed quarterly report on Form 10-Q. David, there are no further questions. Thank you again for your attendance at today's meeting and for your continued support of NGM Biopharmaceuticals. Have a great day.